Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for RCUS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 127.00M
March 31, 2026 125.50M
December 31, 2025 125.30M
September 30, 2025 107.10M
June 30, 2025 106.40M
March 31, 2025 105.90M
December 31, 2024 92.20M
September 30, 2024 91.50M
June 30, 2024 91.30M
March 31, 2024 90.90M
December 31, 2023 75.50M
September 30, 2023 74.80M
June 30, 2023 74.50M
March 31, 2023 73.10M
December 31, 2022 72.90M
September 30, 2022 72.35M
June 30, 2022 72.09M
March 31, 2022 71.62M
Date Value
December 31, 2021 70.78M
September 30, 2021 70.24M
June 30, 2021 71.37M
March 31, 2021 70.97M
December 31, 2020 65.11M
September 30, 2020 64.92M
June 30, 2020 58.94M
March 31, 2020 45.98M
December 31, 2019 45.92M
September 30, 2019 45.84M
June 30, 2019 45.85M
March 31, 2019 44.53M
December 31, 2018 44.54M
September 30, 2018 44.45M
June 30, 2018 44.46M
March 31, 2018 44.45M
December 31, 2017 43.75M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 114.04M
AVITA Medical, Inc. 30.93M
Iovance Biotherapeutics, Inc. 452.97M
Editas Medicine, Inc. 153.53M
Recursion Pharmaceuticals, Inc. 534.12M